Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Near 52-Week High
- August 12, 2026
- Posted by: Harsh Piplani
- Category: News
Fredun Pharmaceuticals Ltd. Share Price is Rs 1,319.90, with the stock trading within 2% of its 52-week high. Market capitalisation stands at Rs 2,014.34 crore.
Fredun Pharmaceuticals Ltd. Share Price was at Rs 1,319.90 at the time of qualification on 12 August 2026 at 1:31 PM IST, with the stock trading within 2% of its 52-week high and carrying a market capitalisation of Rs 2,014.34 crore. That puts Fredun Pharmaceuticals Ltd. Share Price on the radar of investors tracking stocks that are close to their one-year peaks, especially when the move is supported by underlying financial ratios and industry positioning.
The verified data confirms the price event through the Univest screener, but it does not establish a company-specific catalyst for why Fredun Pharmaceuticals Ltd. Share Price is near its yearly high. Even so, this type of setup often attracts attention because proximity to a 52-week high can reflect sustained investor interest, favourable earnings expectations already embedded in the price, or improving market perception relative to peers.
For Fredun Pharmaceuticals Ltd. Share Price, the immediate context is a Healthcare company in the Pharmaceuticals & Drugs industry trading at a P/E of 48.16 and a P/B of 7.19, with ROE at 11.42 and ROCE at 13.15. Those numbers make the stock worth examining not only as a price-action story but also as a broader stock analysis case. Univest data shows the event clearly; the next step is to understand what the fundamentals and sector comparison say about the move.
Fredun Pharmaceuticals Ltd. Share Price Today: Within 2% of 52-Week High
| Metric | Value |
|---|---|
| LTP at 2% Qualification | Rs 1,319.9 |
| Market Capitalisation | Rs 2,014.34 crore |
| 52-Week High Position | Trading within 2% of its 52-week high |
Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,319.9. Reported volume was 18,071.
Fredun Pharmaceuticals Ltd. Share Price Today stands at Rs 1,319.90, which is also the event qualification price captured by the Univest screener at 1:31:06 PM IST on 12 August 2026. The stock has been identified as trading within 2% of its 52-week high, a condition that places Fredun Pharmaceuticals Ltd. Share Price close to an important reference zone followed by traders, momentum investors and fundamental investors alike.
When a stock trades this close to its one-year peak, attention typically rises because the market is effectively testing whether the current valuation and earnings profile can continue to support elevated levels. In this case, Fredun Pharmaceuticals Ltd. Share Price is attached to a Rs 2,014.34 crore market capitalisation, placing it in a meaningful mid-sized bracket within its industry set. That matters because stocks in this range can draw interest from investors looking beyond very small companies while still seeking sector-specific rerating opportunities.
The verified dataset here confirms the proximity event, but not the trigger behind it. That distinction is important. The fact pattern supports increased market attention to Fredun Pharmaceuticals Ltd. Share Price, yet it does not by itself confirm a breakout, a new high or a specific news-driven move. Instead, the current setup suggests that the stock is being watched because it remains in striking distance of its yearly peak while carrying valuation, profitability and balance-sheet metrics that can now be compared with the wider Pharmaceuticals & Drugs space. That naturally brings the discussion from price action to fundamentals.
Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,014.34 crore |
| P/E Ratio | 48.16x |
| P/B Ratio | 7.19x |
| ROE | 11.42% |
| ROCE | 13.15% |
| EPS | Rs 26.5 |
| Book Value Per Share | Rs 177.38 |
| Dividend Yield | 0.02% |
Fredun Pharmaceuticals Ltd. was valued at a P/E ratio of 48.16x, a P/B ratio of 7.19x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 11.42% and ROCE of 13.15%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 26.5, book value per share of Rs 177.38, dividend yield of 0.02%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 48.16x |
| Benchmark Median P/E | 18.58x |
| Benchmark Average P/E | 60.74x |
| Benchmark P/E Range | 0x to 3,374.81x |
| Company P/B Ratio | 7.19x |
| Benchmark Median P/B | 1.78x |
| Company ROE | 11.42% |
| Benchmark Median ROE | 9.93% |
| Company ROCE | 13.15% |
| Benchmark Median ROCE | 12.96% |
| Company Market Capitalisation | Rs 2,014.34 crore |
| Benchmark Median Market Cap | Rs 145.18 crore |
Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 48.16x, which is above the benchmark median of 18.58x, a difference of +159.2%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 11.42%, which is above the benchmark median of 9.93%, a difference of +15.01%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 13.15%, which is above the benchmark median of 12.96%, a difference of +1.47%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sakar Healthcare Ltd. | SAKAR | 2,013.17 | 58.79 | 6.34 | 11.88 | 13.16 |
| Venus Remedies Ltd. | VENUSREM-BE | 2,031.58 | 18.16 | 3.07 | 9.85 | 7.89 |
| Indoco Remedies Ltd. | INDOCO | 2,038.53 | 355.2 | 1.99 | 12.85 | 15.67 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,061.86 | 43.16 | 1.65 | -0.78 | 8.31 |
| Hester Biosciences Ltd. | HESTERBIO | 2,128.33 | 15.51 | 4.64 | 16.17 | 14.12 |
Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 48.16x compared with the displayed peer median of 43.16x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.42% compares with a peer median of 11.88% across the companies shown in the table. ROCE stood at 13.15% versus the displayed peer median of 13.16%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 2,014.34 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching Fredun Pharmaceuticals Ltd.
- Fredun Pharmaceuticals Ltd. Share Price is at Rs 1,319.90 and the stock is trading within 2% of its 52-week high.
- The company’s market capitalisation of Rs 2,014.34 crore places it among larger names within a 135-company same-industry benchmark.
- Valuation is notable, with P/E at 48.16 and P/B at 7.19, both demanding closer scrutiny against profitability.
- ROE of 11.42 and ROCE of 13.15 are above the industry median levels of 9.93 and 12.96 respectively.
- Peer comparison shows Fredun Pharmaceuticals Ltd. Share Price trades at a higher P/B than Sakar, Venus, Indoco, Ind-Swift and Hester.
About Fredun Pharmaceuticals Ltd.
Fredun Pharmaceuticals Ltd. operates in the Healthcare sector and is classified under the Pharmaceuticals & Drugs industry. Based on the supplied dataset, the company is part of a listed industry universe where investors often compare valuation, profitability and market capitalisation closely because business models can vary across formulations, manufacturing, healthcare products and related pharmaceutical operations.
In market terms, Fredun Pharmaceuticals Ltd. sits in a peer cluster around the Rs 2,000 crore mark, which makes it relevant in comparative industry analysis. That size puts the company far above the median industry market capitalisation of Rs 145.18 crore and above the average of Rs 472.98 crore in the supplied benchmark set. For investors following Fredun Pharmaceuticals Ltd. Share Price, the company’s profile is currently defined less by descriptive business disclosures in the dataset and more by its position as a reasonably large listed Pharmaceuticals & Drugs player trading close to its one-year high while carrying premium valuation multiples versus many industry peers.
Track Fredun Pharmaceuticals Ltd. Share Price on Univest
Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors using Univest can track Fredun Pharmaceuticals Ltd. Share Price with live market monitoring tools alongside 52-week levels, valuation ratios, profitability indicators and broader market insights. That makes it easier to place a near-52-week-high move in context rather than viewing price action in isolation.
On Univest, users can follow Fredun Pharmaceuticals Ltd. Share Price Today, compare sector and peer metrics, review technical indicators when available, and monitor how the stock is positioned within Healthcare and Pharmaceuticals & Drugs. For a stock trading close to its yearly high, that broader framework can be useful in separating headline attention from measurable business and valuation context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Fredun Pharmaceuticals Ltd. Share Price today?
Ans. Fredun Pharmaceuticals Ltd. Share Price was Rs 1,319.90 at the event qualification time on 12 August 2026 at 1:31 PM IST. The stock was also identified by the screener as trading within 2% of its 52-week high.
Why is Fredun Pharmaceuticals Ltd. Share Price in focus today?
Ans. Fredun Pharmaceuticals Ltd. Share Price is in focus because the stock is trading within 2% of its 52-week high. With a market capitalisation of Rs 2,014.34 crore, that proximity naturally draws interest from momentum and valuation-focused investors.
What is the market capitalisation of Fredun Pharmaceuticals Ltd.?
Ans. Fredun Pharmaceuticals Ltd. has a market capitalisation of Rs 2,014.34 crore. In the supplied same-industry benchmark of 135 companies, that is far above the median market cap of Rs 145.18 crore and the average of Rs 472.98 crore.
What do the valuation ratios say about Fredun Pharmaceuticals Ltd. Share Price?
Ans. Fredun Pharmaceuticals Ltd. Share Price trades at a P/E of 48.16 and a P/B of 7.19. Those levels are above the industry median P/E of 18.58 and median P/B of 1.78 in the supplied Pharmaceuticals & Drugs benchmark.
How profitable is Fredun Pharmaceuticals Ltd. based on the supplied data?
Ans. Fredun Pharmaceuticals Ltd. reports ROE of 11.42 and ROCE of 13.15. Both are above the industry median figures of 9.93 and 12.96 respectively, although ROCE remains below the industry average of 15.54.
What are the EPS, book value and dividend yield of Fredun Pharmaceuticals Ltd.?
Ans. Fredun Pharmaceuticals Ltd. has EPS of Rs 26.5, book value per share of Rs 177.38 and dividend yield of 0.02. These figures help frame earnings power, accounting net worth and the stock’s relatively small historical payout profile.
How does Fredun Pharmaceuticals Ltd. compare with selected peers?
Ans. Fredun Pharmaceuticals Ltd. sits near peers such as Sakar Healthcare, Venus Remedies, Indoco Remedies, Ind-Swift Laboratories and Hester Biosciences on market cap. Its P/B of 7.19 is higher than all five, while profitability is mixed across the group.
Which sector and industry does Fredun Pharmaceuticals Ltd. belong to?
Ans. Fredun Pharmaceuticals Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark compares it with 135 same-industry companies, while the broader Healthcare sector coverage in the dataset includes 195 companies.
